Axitinib Poised To Join Pfizer's RCC Drug Portfolio In 2012
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pfizer Inc.'s second-generation VEGF inhibitor axitinib has been granted a standard 10-month review by FDA for the second-line treatment of advanced renal cell carcinoma, positioning it for a potential launch in the first half of 2012.
You may also be interested in...
Astellas Pays $125MM Up-Front To Share Rights To AVEO's Tivozanib
In a worldwide deal excluding Asia, the two companies will split both revenues and development costs 50/50 in North America and Europe.
RCC Market Snapshot: In A Crowded Field, What's Next?
Just five years ago, the treatment options for patients with advanced kidney cancer were limited, but today, the market for renal cell carcinoma drugs is one of the most crowded in the oncology field, with six targeted agents on the market and more on the way
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.